Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growrh factors of stem cells

Abstract

A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include but are not limited to alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, diabetes mellitus, amyloid diseases, atherosclerosis, arthritis, osteoporosis, cystic fibrosis. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of one or more compounds that increases the presence of one or more Carbonic Anhydrase Isozymes whose levels have been reduced in the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes, a compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or a compound that when administered promotes the natural generation of the cell specific carbonic anhydrase enzymes within the subject. This method also uses one or more cells specific carbonic anhydrase as growth factors of stem cells for replacing tissues due to injuries or diseases in humans. These methods includes the administering of these compounds over an extended period of time ranging from 6 months until the subject dies.

1 . A method for the Treatment and Prophylaxis of one or a combination of Human disorders and diseases which includes aging in a subject comprising:
 (a) Assaying for the decreased levels of one or more Carbonic Anhydrase Enzyme I (CA-I), Carbonic Anhydrase Enzyme II (CA-II), Carbonic Anhydrase Enzyme III (CA-III), Carbonic Anhydrase Enzyme IV (CA-IV), Carbonic Anhydrase Enzyme V (CA-V), Carbonic Anhydrase Enzyme VI (CA-VI) and Carbonic Anhydrase Enzyme VII (CA-VII) in a tissue of the subject suspected of having a condition of aging wherein said condition of aging is age related chronic neurodegenerative which includes alzheimer's disease; multiple sclerosis; parkinson's disease; amyotrophic lateral sclerosis (Lou Gehrig's disease); autism; age related bone disorders which includes osteoporosis, osteomalacia, arthritis, immune disorders which include diabetes mellitus, systemic lupus erythematosus, Disorders of the Integumentary system and Collagen which includes wrinkling of the skin, cardiomyopathies, amyloid diseases, cystic fibrosis; atherosclerosis   (b) Administering to the subject a pharmaceutically effective non-toxic amount of one or more compounds that increases the level of Carbonic anhydrase enzymes I; II; III; IV; V; VI and VII consisting of acetylcholine; histamine; serotonin; vitamin D3; 1,25, dihydroxyvitamin D3; Zinc; sex hormones which includes testosterone and estrogen; growth hormones; L and D phenylalanine; Androgens which includes DHEA (dehydroepiandrosterone), NSAID (non-steroidal anti-inflammatory drugs), melatonin, selective serotonin re-uptake inhibitors which includes, sertraline, fluoxetine, citalopram, or combinations thereof.   
     
     
         2 . The method of  claim 1 , wherein step (a) comprises determining the levels Carbonic anhydrase enzyme I (CA-I), Carbonic anhydrase enzyme II (CA-II), Carbonic anhydrase enzyme III (CA-III), Carbonic anhydrase enzyme IV (CA-IV), Carbonic anhydrase enzyme V (CA-V), Carbonic anhydrase enzyme VI (CA-VI), Carbonic anhydrase enzyme VII (CA-VII) or any combination thereof in the blood of the subject. 
     
     
         3 . The method of  claim 1  step (a) comprises determining the levels of Carbonic anhydrase enzymes I (CA-I), II (CA-II, III, IV, V, VI, VII or any combination thereof in the biopsied tissue of a subject. 
     
     
         4 . The method of  claim 1  step (a) comprises determining the levels of Carbonic anhydrase enzymes I, II, III, IV, V, VI, VII or any combination thereof in the cerebro-spinal fluid of a subject. 
     
     
         5 . The method of  claim 1  wherein the subject is human 
     
     
         6 . A method for reducing the signs and symptoms associated with age related chronic neurodegenerative disorders which includes alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, parkinson's disease; autism; bone disorders which includes osteoporosis, osteomalacia, arthritis; immune disorders which includes diabetes mellitus, systemic lupus erythematosus; Disorders of the Integumentary system and collagen which includes wrinkling of the skin; cardiomyopathies; atherosclerosis; amyloidosis; cystic fibrosis in a patient suspected of having signs and symptoms, the method comprising:
 (a) assaying for a decrease in the level of one or more carbonic anhydrase Enzymes in a bodily sample from the said subject and   (b) administering to said subject a pharmaceutical effective non-toxic amount of acetylcholine; histamine; serotonin; Vitamin D3; 1,25, dihydroxyvitamin D3; Zinc; sex hormones which includes testosterone; estrogen; growth Hormones; androgens which includes DHEA (dehydroepiandrosterone; L and D Phenylalanine.   
     
     
         7 . The method of  claim 1 , wherein the condition of aging is age-related bone disorders which includes osteoporosis, osteomalacia, arthritis 
     
     
         8 . The method of  claim 1 , wherein the condition of aging is age-related chronic neurological disorders which includes alzheimer's disease, multiple sclerosis, Lou Gehrig's Disease, Parkinson's disease 
     
     
         9 . The method of  claim 1 , wherein the condition of aging is age-related immune disorders which includes diabetes mellitus, systemic lupus erythematosus 
     
     
         10 . The method of  claim 1  wherein the condition is age-related disorders of the integumentary system and collagen which includes wrinkling of the skin 
     
     
         11 . The method of  claim 1  wherein the condition is age-related amyloidosis 
     
     
         12 . The method of  claim 1  wherein the condition is age-related atherosclerosis 
     
     
         13 . The method of  claim 1  wherein the condition is cystic fibrosis 
     
     
         14 . The method of  claim 1  wherein the condition is amyotrophic lateral sclerosis 
     
     
         15 . The method of  claim 1  wherein the condition is parkinson's disease 
     
     
         16 . The method of  claim 1  wherein the condition is autism 
     
     
         17 . The method of  claim 1  wherein the condition is osteoarthris 
     
     
         18 . The method of  claim 1  wherein the condition is age related osteoporosis 
     
     
         19 . The method of  claim 1  wherein the condition is alzheimer's disease 
     
     
         20 . The method of  claim 1 , wherein after treatment, the patient have reduced signs and symptoms of age-related bone disorders which include osteoporosis, osteomalacia, arthritis; chronic neurodegenerative disorders which includes alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (Lou Gehrig's Disease), autism; Parkinson's disease; Immune disorders which includes Diabetes Mellitus, Systemic Lupus Erythematosus; Disorders of the Integumentary system and Collagen disease which includes wrinkling of the skin; cardiomyopathies; amyloidosis; atherosclerosis; cystic fibrosis.